[go: up one dir, main page]

WO2024223928A3 - Coreceptor chimeric antigen receptor - Google Patents

Coreceptor chimeric antigen receptor Download PDF

Info

Publication number
WO2024223928A3
WO2024223928A3 PCT/EP2024/061710 EP2024061710W WO2024223928A3 WO 2024223928 A3 WO2024223928 A3 WO 2024223928A3 EP 2024061710 W EP2024061710 W EP 2024061710W WO 2024223928 A3 WO2024223928 A3 WO 2024223928A3
Authority
WO
WIPO (PCT)
Prior art keywords
chimeric antigen
antigen receptor
cocar
coreceptor
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/061710
Other languages
French (fr)
Other versions
WO2024223928A2 (en
Inventor
Rudolf ÜBELHART
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanudis GmbH
Original Assignee
Vanudis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanudis GmbH filed Critical Vanudis GmbH
Priority to AU2024264153A priority Critical patent/AU2024264153A1/en
Publication of WO2024223928A2 publication Critical patent/WO2024223928A2/en
Publication of WO2024223928A3 publication Critical patent/WO2024223928A3/en
Priority to IL324124A priority patent/IL324124A/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a co-receptor chimeric antigen receptor (CoCAR) capable of binding LCK, combinations of a co-receptor chimeric antigen receptor and a CAR, nucleic acid constructs encoding such CoCAR, recombinant cells engineered to express such CoCAR and pharmaceutical compositions comprising the same. The present invention further provides the use thereof in the treatment of diseases preferably characterized by expression of a tumor-associated antigen.
PCT/EP2024/061710 2023-04-27 2024-04-29 Coreceptor chimeric antigen receptor Pending WO2024223928A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024264153A AU2024264153A1 (en) 2023-04-27 2024-04-29 Coreceptor chimeric antigen receptor
IL324124A IL324124A (en) 2023-04-27 2025-10-21 Chimeric antigen receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23170480.0 2023-04-27
EP23170480 2023-04-27

Publications (2)

Publication Number Publication Date
WO2024223928A2 WO2024223928A2 (en) 2024-10-31
WO2024223928A3 true WO2024223928A3 (en) 2024-12-12

Family

ID=86272304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/061710 Pending WO2024223928A2 (en) 2023-04-27 2024-04-29 Coreceptor chimeric antigen receptor

Country Status (3)

Country Link
AU (1) AU2024264153A1 (en)
IL (1) IL324124A (en)
WO (1) WO2024223928A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193231A1 (en) * 2017-04-18 2018-10-25 Autolus Limited Cell

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459990B (en) 2014-02-07 2021-06-01 麦克马斯特大学 Trifunctional T cell antigen conjugate and preparation method and use thereof
BR112018009129A2 (en) 2015-11-04 2019-02-26 J. PRICEMAN Saul her2 targeting chimeric antigen receptors
US20240156864A1 (en) 2019-10-31 2024-05-16 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018193231A1 (en) * 2017-04-18 2018-10-25 Autolus Limited Cell

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHER W. HELSEN ET AL: "The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity", NATURE COMMUNICATIONS, vol. 9, no. 1, 3 August 2018 (2018-08-03), XP055583660, DOI: 10.1038/s41467-018-05395-y *

Also Published As

Publication number Publication date
AU2024264153A1 (en) 2025-11-13
IL324124A (en) 2025-12-01
WO2024223928A2 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
US11572415B2 (en) Multivalent FV antibodies
CN106536563B (en) Chimeric antigen receptors
PH12020550600A1 (en) Novel engineered t cell receptors and immune therapy using the same
TW201908340A (en) Modified bispecific polypeptide molecule
JP2018524326A5 (en)
JP2019534002A (en) Targeted mutant interferon-gamma and uses thereof
EP2826791A3 (en) Humanized anti-C5aR antibodies
WO2015036582A2 (en) Tetravalent homodimeric antigen-binding proteins
JP2018519296A5 (en)
WO2006082515A3 (en) Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
WO2016176651A2 (en) Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
TW200720439A (en) Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
CN119895039A (en) Mutant polypeptides, compositions comprising the mutant polypeptides and uses thereof
US20190099461A1 (en) Rna viruses for immunovirotherapy
TW202144396A (en) Inhibitory chimeric receptor architectures
WO2023133357A2 (en) Engineered t cells
US20180028633A1 (en) Chimeric antigen receptor combination therapy for treating tumors
WO2024223928A3 (en) Coreceptor chimeric antigen receptor
CA3185087A1 (en) Immunostimulatory adjuvants
US20250195651A1 (en) Use of antigen presenting cells to enhance car-t cell therapy
CN114761430A (en) Chimeric protein targeting PD-L1 and application thereof
KR20220087431A (en) T cell receptors and methods of use thereof
UA100531C2 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
JP7669347B2 (en) T cell receptors and methods of use thereof
JP7669345B2 (en) T cell receptors and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24724104

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 324124

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: AU2024264153

Country of ref document: AU

Ref document number: 826335

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 324124

Country of ref document: IL

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025023127

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2024264153

Country of ref document: AU

Date of ref document: 20240429

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11202507140T

Country of ref document: SG

Ref document number: 2024724104

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11202507140T

Country of ref document: SG